Novavax sees positive results in Matrix-M adjuvant
The results from the Phase 1/2A clinical trial, which was run by Genocea Biosciences, Inc., the maker of GEN-003, showed the vaccine was capable of significantly blunting HSV-2 and reducing viral shedding. No serious adverse events related to the vaccine were found.
"The strong showing of Genocea's vaccine candidate, which includes our proprietary adjuvant Matrix-M, underscores the potential of the adjuvant to Novavax, and the value of our recent acquisition of Isconova," Stan Erck, the president and chief executive officer of Novavax, said.
Matrix-M is a vaccine adjuvant that is developed by Novavax. Adjuvants can enhance the efficacy of a vaccine while also maintaining the usual safety levels.
In the U.S. based clinical trial, 143 volunteers with moderate to severe HSV-2 were enrolled. After the positive results of the Phase 1/2A clinical trial, a Phase 2 trial was announced.
"The early clinical response to GEN-003 in this trial is unprecedented in HSV-2," Chip Clark, the president and chief executive officer of Genocea, said. "We are proud to be pioneers in the field of T cell-directed vaccines."